Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Genzyme Corporation    GENZ

GENZYME CORPORATION

(GENZ)
SummaryNewsCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

GENZYME CORP.GNL : Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/28/2011 | 07:35am EST

Genzyme Corporation (NASDAQ: GENZ) today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards (PAL Awards). A global grant program, the Genzyme PAL Awards will support non-profit organizations that work on behalf of patients living with lysosomal storage disorders (LSDs), a group of rare, inherited disorders that cause progressive and debilitating health problems. A total of $50,000 will be awarded through a competitive application process to organizations that seek funding for new initiatives that support the LSD patient community.

?For 30 years, Genzyme has been supporting patients through pioneering new treatments, free drug programs and through ongoing partnerships with patient organizations that serve the LSD patient community,? said Genzyme's Director of Patient Advocacy, Jamie Manganello. ?International Rare Disease Day is a great moment to launch the PAL Awards to commemorate the progress that has been made in partnership with the patient community, and as a reminder of our commitment to the work that is still ahead for us on behalf of patients and families affected by rare diseases.?

Organizations may apply for a Genzyme PAL Award for programs that support disease awareness, advocacy on behalf of patient communities, patient education and patient care, support and communication networks. This grant program is supplemental to Genzyme's existing grants program and will not replace the contributions made locally each year to support advocacy groups. Proposals will be reviewed by an external review committee. Applications must be received by June 15, 2011, and the award recipients will be announced by July 31, 2011. For more information on the Genzyme PAL Awards program, or to apply for a grant, please visit www.genzymeadvocacyawards.com.

February 28, 2011 marks the fourth International Rare Disease Day, created by the patient organization EURORDIS and involving rare disease organizations globally. Genzyme is proud to have been a partner each year for International Rare Disease Day, and has organized events at Genzyme locations around this year's theme, ?Rare but Equal.? These events include presentations by patients with rare diseases at Genzyme offices, participation in a public event at the Massachusetts State House and today's launch of the Genzyme PAL Awards.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with approximately 10,000 employees in locations spanning the globe. Genzyme this month announced an agreement to be acquired by sanofi-aventis, and the transaction is expected to close early in the second quarter of this year.

With many established products and services helping patients in 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and immune disease. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Important Information

Genzyme has filed with the Securities and Exchange Commission a Solicitation/Recommendation Statement on Schedule 14D-9 relating to the tender offer by Sanofi-Aventis. Genzyme shareholders are advised to read the company's Solicitation/Recommendation Statement on Schedule 14D-9 because it contains important information. Shareholders may obtain a free copy of the Solicitation/Recommendation Statement on Schedule 14D-9, as well as any other documents filed by Genzyme in connection with the tender offer, free of charge at the SEC's website at http://www.sec.gov. In addition, investors can obtain free copies of these documents from Genzyme by directing a request to Genzyme at 500 Kendall Street, Cambridge, MA 02142, Attention: Shareholder Relations Department, or by calling 617-252-7500 and asking for the Shareholder Relations Department.

Media Contact:
Genzyme Corporation
Lori Gorski, 617-768-9344
Lori.gorski@genzyme.com
or
Investor Contact:
Patrick Flanigan, 617-768-6563


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENZYME CORPORATION
2011GENZYME CORP.GNL : Mipomersen Data Presented at European Atherosclerosis Society..
PU
2011GENZYME CORP.GNL : Genzyme Board Unanimously Recommends that Shareholders Accept..
BU
2011GENZYME CORP.GNL : Genzyme Completes Sale of Pharmaceuticals Business to Interna..
BU
2011GENZYME CORP.GNL : Genzyme Recognizes International Rare Disease Day by Launchin..
BU
2011GENZYME CORP.GNL : Three-Year Data from Phase 2 Trial of Genzyme Gaucher Disease..
BU
2011GENZYME CORP.GNL : Genzyme Reports Financial Results for Fourth Quarter of 2010 ..
BU
2011GENZYME CORP.GNL : Genzyme Completes Sale of Diagnostics Business to Sekisui Che..
BU
2011GENZYME CORP.GNL : Genzyme Will Allow Sanofi-Aventis to Conduct Due Diligence
BU
2011GENZYME CORP.GNL : Genzyme to Build Additional Plant to Support Growth of Myozym..
BU
2011GENZYME CORP.GNL : Genzyme Financial Recovery Continues in Fourth Quarter
BU
More news
Sector and Competitors
1st jan.Capitalization (M$)
GENZYME CORPORATION0
GILEAD SCIENCES7.24%83 411
VERTEX PHARMACEUTICALS34.72%57 362
REGENERON PHARMACEUTICALS-0.33%40 268
WUXI APPTEC CO., LTD.71.04%21 133
GENMAB51.29%15 619